(Press-News.org) CHICAGO, IL (May 30, 2014)—Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.
During the study, 36 patients with muscle-invasive bladder cancer received chemotherapy before surgery, consisting of an accelerated regimen of methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC). By the time surgery rolled around, 14 patients appeared cancer-free. All but one of these patients carried mutations in at least one of three specific genes; none of these mutations were present in any of the people who still harbored traces of cancer after AMVAC.
These results suggest that doctors may one day sequence patients' tumors for the presence of these three mutations, to determine who will likely benefit most from chemotherapy before surgery, said Elizabeth R. Plimack, MD, Attending Physician in the Department Medical Oncology at Fox Chase.
"The purpose of the study is to find ways to identify patients who are likely to respond to early chemotherapy," said Dr. Plimack. "For those patients who won't benefit from it, we can send them directly to surgery to save time. But if they carry at least one of these mutations, we can treat them knowing they are likely to respond," she noted.
To uncover a genetic pattern that predicted responses to AMVAC, Dr. Plimack and her colleagues in collaboration with Foundation Medicine sequenced 287 cancer-related genes in tissue samples taken before patients underwent chemotherapy. The analysis clearly landed on three genes, all associated with repairing damaged DNA, carried by all but one of the people who benefited from chemotherapy. To see such a clear distinction between the genetic profiles of responding and non-responding tumors is remarkable, Dr. Plimack added. "It is unusual to see statistics this good," she said.
Additionally, patients whose cancer disappeared after AMVAC tended to carry more mutations in their tumors than those with residual cancer at the time of surgery.
It makes sense that the three key genes are associated with DNA repair, said Dr. Plimack. Patients who carry these mutations will likely have more mutations because their cells cannot easily repair cellular damage, so when cancer starts, mutations quickly accumulate. But since cisplatin works by further damaging DNA, these same tumors are more likely to succumb to its effects, since they lack mechanisms to sidestep chemotherapy. "These patients may have developed cancer because a damaged cell couldn't repair itself, but once they have cancer, the defective DNA repair machinery makes the tumor more likely to respond to chemotherapy because the cells can't repair the additional damage caused by cisplatin," said Dr. Plimack.
The results point to a new way to screen patients to select those who will benefit most from cisplatin-based chemotherapy. Looking for these mutations involves a genomic sequencing test that's already commercially approved, and available to any clinician, said Dr. Plimack. But she cautioned that more work needs to be done, and she and her colleagues are now testing tissue samples from another set of patients to make sure the results hold up. "Although the statistics are exciting, and the mechanism makes sense, the results are preliminary. We do not recommend treatment decisions be made based on this test until it is validated"
INFORMATION:
Dr. Plimack's co-authors include Roland Dunbrack, Timothy Brennan, Qiong Wei, Roman Yelensky, Ilya Serebriiskii, Jean H. Hoffman-Censits, Alexander Kutikov, R. Katherine Alpaugh, Essel Dulaimi, Rosalia Viterbo, Richard E. Greenberg, David Y. T. Chen, Costas D. Lallas, Yu-Ning Wong, Edouard John Trabulsi, Norma Alonzo Palma, Vincent A. Miller, Erica Golemis, and Eric A Ross.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at http://www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427). END
Genetic profile predicts which bladder cancer patients will benefit from early chemotherapy
2014-05-30
ELSE PRESS RELEASES FROM THIS DATE:
For the first time in the lab, researchers see stem cells take key step toward development
2014-05-30
CHAMPAIGN, Ill. — The gap between stem cell research and regenerative medicine just became a lot narrower, thanks to a new technique that coaxes stem cells, with potential to become any tissue type, to take the first step to specialization. It is the first time this critical step has been demonstrated in a laboratory.
University of Illinois researchers, in collaboration with scientists at Notre Dame University and the Huazhong University of Science and Technology in China, published their results in the journal Nature Communications.
"Everybody knows that for an embryo ...
Trial uncovers potential dangers of chemotherapy regimen for bladder cancer patients
2014-05-30
CHICAGO, IL (May 30, 2014)—Patients with muscle-invasive bladder cancer often benefit from chemotherapy before surgery to remove the tumor, but a test of one regimen by researchers at Fox Chase Cancer Center was halted when too many people experienced serious side effects such as heart attacks and blood clots in the legs and lungs.
All of the 31 patients included in the study received a combination of gemcitabine and cisplatin, two drugs normally administered for 12 weeks before surgery to remove the tumors. This became the standard of care after one study looked back, ...
Atomic structure of essential circadian clock protein complex determined
2014-05-30
Structural biologists have made important progress towards better understanding the functioning of the circadian clock. The circadian or inner clock coordinates the sleep-wake rhythm and many other body processes that regulate, for example, metabolism, blood pressure, and the immune system. A research team led by Professor Eva Wolf, recently appointed Professor of Structural Biology at the Institute of General Botany of Johannes Gutenberg University Mainz (JGU) and Adjunct Director at the Institute of Molecular Biology (IMB), has for the first time identified the molecular ...
Coaxing iPS cells to become more specialized prior to transplantation cuts rejection risk
2014-05-30
STANFORD, Calif. — For many scientists, the clinical promise of stem cells has been dampened by very real concerns that the immune system will reject the transplanted cells before they could render any long-term benefit. Previous research in mice has suggested that even stem cells produced from the subject's own tissue, called iPS cells, can trigger an immune attack.
Now researchers at the Stanford University School of Medicine have found that coaxing iPS cells in the laboratory to become more-specialized progeny cells (a cellular process called differentiation) before ...
Standard approaches to menopause symptoms discount non-Western experiences
2014-05-30
Dr Mwenza T. Blell of the University of Bristol interviewed 257 British Pakistani women aged 39-61 living in West Yorkshire and found that the standard checklist approach to studying menopause symptoms, which ignores women's understanding of their own experience, leaves researchers and clinicians with gaps in their knowledge of the 'true' symptoms of menopause.
Many previous studies into the menopause have relied on standardised checklists, such as the Blatt-Kupperman index and the Menopause Symptom Checklist, that were derived from the clinical experiences of women living ...
New software tool identifies genetic mutations that influence disease risk
2014-05-30
HOUSTON-Researchers at The University of Texas MD Anderson Cancer Center and other institutions have applied a newly developed software tool to identify genetic mutations that contribute to a person's increased risk for developing common, complex diseases, such as cancer. The research is published in the May 2014 edition of the journal Nature Biotechnology.
The technology, known as pVAAST (pedigree Variant Annotation, Analysis and Search Tool), combines two different statistical methods used for identifying disease-causing gene mutations. This combination approach outperforms ...
Study links urbanization and future heat-related mortality
2014-05-30
TEMPE, Ariz. – Phoenix stands at a parched crossroads. Global scale climate change is forecast to bring hotter summers and more extreme heat to the Valley, but regional urbanization also will impact temperatures experienced by residents.
So how should Phoenix grow knowing that such growth could cause temperatures to increase in the future and bring added health risks? Should the city deploy mitigating technologies to help fight summer's heat? Would adopting a low-growth strategy reduce the adverse health consequences of hot weather?
New Arizona State University research ...
DNA-binding fluorescent dyes detect real-time cell toxicity during drug screening
2014-05-30
New Rochelle, NY, May 30, 2014—High throughput screening of compounds in live cells is a powerful approach for discovering new drugs, but the potential for cell toxicity must be considered. A novel technique that uses DNA-binding fluorescent dyes to evaluate the cytotoxicity of an experimental compound in real-time during screening, saving time and resources, is described in ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the ASSAY and Drug Development Technologies website.
Lucius Chiaraviglio ...
Study explains how green tea could reduce pancreatic cancer risk
2014-05-30
LOS ANGELES – (May 30, 2014) – Green tea and its extracts have been widely touted as potential treatments for cancer, as well as several other diseases. But scientists have struggled to explain how the green tea and its extracts may work to reduce the risk of cancer or to slow the growth of cancer cells.
A study recently published online by the journal, Metabolomics, offers an explanation that researchers say could open a new area of cancer-fighting research. The study reports that EGCG, the active biologic constituent in green tea, changed the metabolism of pancreatic ...
Research shows overall survival benefit for patients with Stage III soft tissue sarcomas
2014-05-30
CHICAGO, IL (May 30, 2014)—Fox Chase Cancer Center researchers have carried out the first retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS), adjusted for socioeconomic status and other variables. The findings show that regardless of socioeconomic status and comorbidities, adjuvant chemotherapy improved survival by approximately 23 percent in stage III STS. Study leader Sujana Movva, MD, Medical Oncologist at Fox Chase, will present the findings the 50th Annual Meeting of the American Society ...